These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21239771)

  • 1. New trends in the standard of care for initial therapy of acute myeloid leukemia.
    Fernandez HF
    Hematology Am Soc Hematol Educ Program; 2010; 2010():56-61. PubMed ID: 21239771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach.
    Fernandez HF; Rowe JM
    Curr Opin Hematol; 2010 Mar; 17(2):79-84. PubMed ID: 20087177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)?
    Rowe JM
    Best Pract Res Clin Haematol; 2009 Dec; 22(4):509-15. PubMed ID: 19959101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
    Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
    Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment of acute myeloid leukemia.
    Roboz GJ
    Curr Opin Oncol; 2012 Nov; 24(6):711-9. PubMed ID: 23014187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines.
    Kim DS; Kang KW; Lee SR; Park Y; Sung HJ; Kim SJ; Choi CW; Kim BS
    Ann Hematol; 2015 Sep; 94(9):1485-92. PubMed ID: 25944346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the best induction regimen for acute myelogenous leukemia?
    Rowe JM
    Leukemia; 1998 Sep; 12 Suppl 1():S16-9. PubMed ID: 9777889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).
    Petersdorf SH; Rankin C; Head DR; Terebelo HR; Willman CL; Balcerzak SP; Karnad AB; Dakhil SR; Appelbaum FR
    Am J Hematol; 2007 Dec; 82(12):1056-62. PubMed ID: 17696203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The blind men and the AML elephant: can we feel the progress?
    Tauro S
    Blood Cancer J; 2016 May; 6(5):e424. PubMed ID: 27176800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Myeloid Leukemia: Past, Present, and Prospects for the Future.
    Short NJ; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S25-9. PubMed ID: 27521321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consolidation therapy: what should be the standard of care?
    Rowe JM
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):53-60. PubMed ID: 18342812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate-risk acute myeloid leukemia therapy: current and future.
    Döhner K; Paschka P
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):34-43. PubMed ID: 25696832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
    Pigneux A; Harousseau JL; Witz F; Sauvezie M; Bene MC; Luquet I; Hunault-Berger M; Recher C; Lioure B; Himberlin C; Escoffre-Barbe M; Berthou C; Lissandre S; Fegueux N; Cahn JY; Jourdan E; Dreyfus F; Reiffers J; Milpied N; Ifrah N
    J Clin Oncol; 2010 Jun; 28(18):3028-34. PubMed ID: 20479424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia].
    Qian SX; Li JY; Wu HX; Lu H; Qiu HX; Chen LJ; Lu RN; Xu W; Sheng RL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):209-13. PubMed ID: 19236781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.